• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

Roivant and Arbutus launch Genevant to develop new RNA drugs

April 13, 2018
By Michael Fitzhugh
Genevant Sciences Ltd., a new Cambridge, Mass.-based venture with $37.5 million in committed seed funding from Roivant Sciences Ltd., is aiming to get five to 10 RNA-based therapies into the clinic by 2020 using technology from Vancouver, British Columbia-based Arbutus Biopharma Corp. The jointly owned company will develop RNAi, mRNA and gene editing candidates in-house, a departure from Roivant's typical in-licensing strategy. Genevant will focus on a wide range of genetic diseases, both orphan and non-orphan, Roivant spokesman Paul Davis told BioWorld.
Read More

Alexion Pharmaceuticals buys Swedish Wilson disease pure-play for $855M

April 11, 2018
By Michael Fitzhugh

Alexion Pharmaceuticals Inc. is offering SEK7.1 billion (US$855 million) to shareholders of Sweden's Wilson Therapeutics AB in a bid to acquire its phase III therapy for Wilson's disease, a rare copper-excess condition. Alexion CEO Ludwig Hantson called the deal "a strong strategic fit" for his company that will play "an important first step in rebuilding our clinical pipeline."


Read More

Magenta secures $52M series C to advance bone marrow transplant drugs

April 11, 2018
By Michael Fitzhugh
Magenta Therapeutics Inc. has closed a $52 million series C financing that it said will be used to advance its portfolio of bone marrow transplantation therapies. The Cambridge, Mass.-based company is testing its most advanced candidate, MGTA-456, in a phase II trial for patients with inherited metabolic diseases.
Read More

Novartis makes $8.7B play for gene therapy developer Avexis

April 10, 2018
By Michael Fitzhugh
Less than a year after landing the first gene therapy approval in the U.S. and just months after licensing certain rights to another, Novartis AG is making yet further bets on the field with an $8.7 billion offer to buy Chicago-based Avexis Inc., a company developing a gene therapy for spinal muscular atrophy (SMA).
Read More

Sigilon inks $473M type 1 diabetes deal with Eli Lilly

April 6, 2018
By Michael Fitzhugh
Sigilon Therapeutics Inc., a Cambridge, Mass.-based startup working to encapsulate therapeutic cells for chronic disease inside microspheres invisible to the immune system's normal fibrotic response to foreign implants, has landed a $473 million deal with Eli Lilly & Co. to develop a potential treatment of type 1 diabetes (T1D).
Read More

Sigilon inks $473M type 1 diabetes deal with Eli Lilly

April 5, 2018
By Michael Fitzhugh
Sigilon Therapeutics Inc., a Cambridge, Mass.-based start-up working to encapsulate therapeutic cells for chronic disease inside microspheres invisible to the immune system's normal fibrotic response to foreign implants, has landed a $473 million deal with Eli Lilly & Co. to develop a potential treatment of type 1 diabetes (T1D). The strategic collaboration, which includes $63 million up front plus an equity investment of undisclosed value, marks one of Lilly's biggest insulin-dependent diabetes deals to date, as measured by disclosed initial value, after ill-fated tie-ups with Macrogenics Inc. and Adocia SAS.
Read More

Retrophin launches pivotal kidney disease trial with eye on accelerated approval

April 4, 2018
By Michael Fitzhugh
Aided by regulators' buy-in on an interim endpoint that may hold the key to accelerated approvals in the U.S. and Europe, Retrophin Inc. is kicking off a pivotal phase III test of sparsentan, a potential treatment for the rare kidney disorder focal segmental glomerulosclerosis (FSGS). With the first patient enrolled, the company will pay licensor Ligand Pharmaceuticals Inc. a $4.6 million milestone.
Read More

Interim breast cancer data on Neuvax sends Sellas shares sailing higher

April 3, 2018
By Michael Fitzhugh
Shares of Sellas Life Sciences Group Inc. (Nasdaq:SLS) jumped 151 percent to close at $8.65 on Monday after the company said an interim analysis of an exploratory phase IIb study seeking the right patient population for its cancer immunotherapy, Neuvax (nelipepimut-S), showed it working synergistically with Herceptin (trastuzumab, Roche Holding AG), making a "clinically meaningful difference" in median disease-free survival for women with triple-negative breast cancer (TNBC).
Read More

Pfizer's tafamidis ATTR-ACTs new attention with transthyretin cardiomyopathy data

April 2, 2018
By Michael Fitzhugh
A top-line win for Pfizer Inc.'s tafamidis, a small-molecule drug in phase III testing to treat a rare and fatal condition associated with progressive heart failure, has shaken up competitive outlooks for Alnylam Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc., both of which are developing alternate therapies in the space. The ATTR-ACT trial, in transthyretin cardiomyopathy, found tafamidis provided a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations vs. placebo at 30 months. It was the first pivotal trial to test a pharmacological treatment for the condition.
Read More

Medicinova shares tumble on failed substance abuse trial

March 30, 2018
By Michael Fitzhugh
Medicinova Inc.'s ibudilast, an experimental anti-inflammatory and neuroprotective agent that has undergone tests in a wide array of neurological conditions, has failed to help addicts kick methamphetamine (MA) dependence in a phase II study, despite early evidence suggesting that it might.
Read More
Previous 1 2 … 89 90 91 92 93 94 95 96 97 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe